À la une

Retrouvez ici toute l’actualité de Cyclhad et de la communauté en hadronthérapie : projets, événements, avancées cliniques et scientifiques, ainsi que des ressources à découvrir et partager.

Recherche Clinique

MEDICO-ECONOMICS & NETWORKS IN HADRONTHERAPY

Particle therapy combines cutting-edge physics, biology, and clinical care to treat complex cancers. Beyond clinical outcomes, its economic, societal, and scientific impact is substantial. Advanced hadrontherapy centers integrate research, training, and technological innovation, demonstrating sustainable models that enhance patient access, improve quality of care, and support regional healthcare and industrial development.

Lire l'article
Recherche Clinique

MEDICAL PHYSICS, INSTRUMENTATION & TECHNOLOGY IN HADRONTHERAPY

Hadrontherapy is at the forefront of precision oncology, combining advanced physics, engineering, and biology to treat cancer with unmatched accuracy. Innovations in beam delivery, imaging, and treatment planning are expanding the clinical potential of protons, carbon, and helium ions.

Lire l'article
Recherche

RADIOBIOLOGY & CARCINOGENESIS OF PARTICLES

During the Hadrontherapy for Life symposium held in March 2025 in Caen, France, leading international experts outlined how particle therapy can overcome radioresistance, improve tumor control, and spare healthy tissues, driven by advanced in hypoxia targeting, FLASH irradiation, combination approaches, and integrated preclinical-clinical research.

Lire l'article
Recherche Clinique

Symposium international Hadrontherapy for Life (FR)

Découvrez les avancées majeures de l’hadronthérapie et téléchargez le rapport complet du symposium Hadrontherapy for Life.

Lire l'article
Recherche Clinique

CLINICAL INDICATIONS IN CARBON-ION RADIOTHERAPY

During the Hadrontherapy for Life symposium held in March 2025 in Caen, France, leading international experts reviewed global carbon-ion and proton therapy programs, highlighting strategies, emerging outcomes, and ongoing efforts to treat complex and radio-resistant tumors.

Lire l'article

Inscription newsletter

Abonnez-vous à notre newsletter pour recevoir nos contenus et événements exclusifs en avant-première !